title: [Vasculitis: update 2014].
authors.affiliation: Klinik und Poliklinik für Innere Medizin I, Universitätsklinikum Regensburg, und Klinik für Rheumatologie/Klinische Immunologie, Asklepios Klinikum Bad Abbach.
authors.forename: M
authors.initials: M
authors.lastname: Fleck
authors.affiliation: Rheumatologie im Struenseehaus, Hamburg.
authors.forename: P M
authors.initials: PM
authors.lastname: Aries
authors.affiliation: Medizinische Klinik III, Klinik für Nephrologie und Rheumatologie, Universitätsklinikum Hamburg-Eppendorf.
authors.forename: C
authors.initials: C
authors.lastname: Iking-Konert
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D000069285:Infliximab; D012254:Ribavirin / Q000627:therapeutic use*; D000069283:Rituximab; D014657:Vasculitis / Q000175:diagnosis* / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D012254:Ribavirin; D000069283:Rituximab; D000069285:Infliximab; C502936:tocilizumab